8-K: Celcuity Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update

Celcuity Inc. announced its first quarter 2024 financial results, highlighting progress in clinical trials and a strong cash position.

Summary

• Celcuity Inc. reported a net loss of $21.6 million, or $0.64 per share, for the first quarter of 2024, compared to a net loss of $11.9 million, or $0.55 per share, for the same period in 2023.
• Total operating expenses increased to $22.5 million, up from $12.6 million in the first quarter of 2023, with research and development expenses accounting for $20.7 million of the total.
• The increase in R&D expenses was primarily due to activities supporting the VIKTORIA-1 Phase 3 trial and the initiation of the CELC-G-201 Phase 1b/2 clinical trial.
• The company's cash, cash equivalents, and short-term investments totaled $177.7 million as of March 31, 2024, which is expected to fund operations into the first half of 2026.
• The Phase 3 VIKTORIA-1 trial is on track to report topline data for the PIK3CA wild type patient sub-group in the second half of 2024 and for the PIK3CA mutant patient sub-group in the first half of 2025.
• The first patient was dosed in a Phase 1b/2 clinical trial evaluating gedatolisib in combination with darolutamide for metastatic castration resistant prostate cancer in February 2024.
• Initial preliminary data from the Phase 1b/2 trial is expected in the first half of 2025.
• Celcuity appointed Eldon Mayer as Chief Commercial Officer in February 2024 to prepare for the potential commercial launch of gedatolisib.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the progress in clinical trials and strong cash position, but the increased losses and expenses temper the overall outlook.

Positives

• The company has a strong cash position of $177.7 million, which is expected to fund operations into the first half of 2026.
• The Phase 3 VIKTORIA-1 trial remains on track to report topline data in the second half of 2024 for the PIK3CA wild type patient sub-group.
• The first patient was dosed in the Phase 1b/2 clinical trial for prostate cancer in February 2024.
• The appointment of a Chief Commercial Officer indicates progress towards commercialization of gedatolisib.

Negatives

• The company reported a net loss of $21.6 million for the first quarter of 2024, which is significantly higher than the $11.9 million loss in the same period of 2023.
• Operating expenses increased substantially to $22.5 million in Q1 2024, compared to $12.6 million in Q1 2023.
• Research and development expenses increased to $20.7 million in Q1 2024, up from $11.3 million in Q1 2023.

Risks

• The company is subject to risks related to clinical trial delays, regulatory approvals, and market acceptance of its products.
• The company's financial performance is heavily dependent on the success of its clinical trials and the commercialization of gedatolisib.
• Increased operating expenses, particularly in research and development, could impact the company's financial stability if clinical trials are not successful.

Future Outlook

The company expects its current cash position to fund operations into the first half of 2026. Topline data from the VIKTORIA-1 trial is expected in the second half of 2024 for the PIK3CA wild type patient sub-group and in the first half of 2025 for the PIK3CA mutant patient sub-group. Initial preliminary data from the Phase 1b/2 trial for prostate cancer is expected in the first half of 2025.

Management Comments

• Brian Sullivan, Celcuity's CEO, stated that the company continued to execute well this quarter, with the VIKTORIA-1 study remaining on track and the first patient dosed in the Phase 1b/2 trial for prostate cancer.
• Management believes non-GAAP adjusted net loss better enables Celcuity to focus on cash used in operations.

Industry Context

This announcement reflects the ongoing challenges and high costs associated with clinical-stage biotechnology companies. The focus on clinical trial progress and financial runway is typical for companies in this sector. The company is competing with other companies developing targeted therapies for oncology.

Comparison to Industry Standards

• The increase in R&D spending is typical for a clinical-stage biotech company advancing multiple trials, such as Celcuity. Companies like Arcus Biosciences and Relay Therapeutics also show similar increases in R&D expenses as they progress their clinical programs.
• The cash runway into the first half of 2026 is a positive sign, as many biotech companies face funding challenges. Companies like Iovance Biotherapeutics and CRISPR Therapeutics also focus on maintaining a strong cash position to fund their clinical programs.
• The focus on specific patient sub-groups (PIK3CA wild type and mutant) in the VIKTORIA-1 trial is a common approach in precision medicine, similar to strategies used by companies like Foundation Medicine and Guardant Health in diagnostics and targeted therapies.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the increased net loss but encouraged by the clinical trial progress and cash runway.
• Employees may be impacted by the company's financial performance and the progress of clinical trials.
• Patients may benefit from the potential development of new targeted therapies for cancer.
• Creditors may be reassured by the company's strong cash position.

Next Steps

• The company will continue to enroll patients in the VIKTORIA-1 Phase 3 trial and the Phase 1b/2 trial for prostate cancer.
• Topline data from the VIKTORIA-1 trial for the PIK3CA wild type patient sub-group is expected in the second half of 2024.
• Initial preliminary data from the Phase 1b/2 trial for prostate cancer is expected in the first half of 2025.
• The company will continue to prepare for the potential commercial launch of gedatolisib.

Key Dates

Keywords

gedatolisib, clinical trials, VIKTORIA-1, prostate cancer, breast cancer, oncology, biotechnology, financial results, research and development, cash runway